Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia
Abstract: In acute lymphoblastic leukemia (ALL), the B-cell lymphoma 2 inhibitor venetoclax may enhance the efficacy of chemotherapy, allowing dose reductions. This phase 1b study of venetoclax plus attenuated chemotherapy enrolled 19 patients with ALL either newly diagnosed (aged ≥60 years, n = 11...
Saved in:
Main Authors: | Marlise R. Luskin, Shai Shimony, Julia Keating, Eric S. Winer, Jacqueline S. Garcia, Richard M. Stone, Elias Jabbour, Yael Flamand, Kristen Stevenson, Jeremy Ryan, Zhihong Zeng, Anthony Letai, Marina Konopleva, Nitin Jain, Daniel J. DeAngelo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Blood Advances |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952924006554 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma
by: Prajwal Boddu, et al.
Published: (2017-01-01) -
Hemophagocytic lymphohistiocytosis secondary to refractory acute myeloid leukemia resolved after second line treatment with azacitidine plus venetoclax
by: Claudio Fozza
Published: (2024-01-01) -
Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax
by: Waqas Jehangir, et al.
Published: (2020-01-01) -
Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia
by: Renshi Kawakatsu, et al.
Published: (2025-01-01) -
Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia
by: Carlos Jiménez-Vicente, et al.
Published: (2025-01-01)